|
艾滋新疫苗可弱化病毒
2011年10月01日01:39来源：海峡都市报 据新华社电
本报讯 外国一些研究人员说，一种全新艾滋病疫苗已进入人体测试阶段，有望弱化这种病毒，使它只能引发“轻微慢性感染”。这款疫苗名为MVA-B，以天花疫苗为主体研制，添加了没有复制能力的艾滋病病毒基因。
已有24人使用
以实验鼠和猴子为对象的测试成功后，疫苗进入人体测试阶段。英国《每日邮报》9月29日报道，30名身体健康的志愿者加入测试，其中24人使用疫苗，另外6人使用与疫苗外观类似的安慰剂，以排除安慰剂效应。
安慰剂其实不含任何药物成分。不过，一些病人服用安慰剂后，会因心理预期改变使病情出现缓解。这一现象称为安慰剂效应。
测试结果显示，90%的志愿者显现出对艾滋病病毒的免疫反应，85%志愿者的免疫反应可以保持至少一年。《每日邮报》报道没有提及疫苗组和安慰剂组的具体测试结果。
效果超其他疫苗
研发艾滋病疫苗是科学界不断努力的方向，但困难重重。2009年，泰国一项涉及1.6万名志愿者的研究显示，一种疫苗可以阻止一部分人感染艾滋病，但有效率只有30%。
西班牙高级科学研究委员会教授埃斯特万说：“MVA-B疫苗获证和其他现存（艾滋病）疫苗同样有效，甚至更有效。”
按照埃斯特万的说法，该疫苗的抗艾机理“就像是展示了一幅艾滋病病毒的照片”，作为人体免疫系统识别病毒的模板。
能弱化病毒影响
其实，MVA-B疫苗并不能完全阻止艾滋病病毒入侵，但可以弱化病毒对人体的影响。埃斯特万认为，依据这种防护效果，MVA-B完全有资格成为“有前途的疫苗”。
“如果（艾滋病）病毒进入人体并试图在细胞中复制，免疫系统则准备好阻止它的活动并摧毁遭感染的细胞。”
也就是说，在MVA-B的保护下，人体即便感染艾滋病病毒，也不会触发严重并发症，只会引起“轻微慢性感染”，传染性显著降低。一些研究人员说，如果这种疫苗成功通过临床测试阶段，那么，今后艾滋病病毒对人类的影响将与现在的疱疹病毒类似。
艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复
 |
| 图示∶2011年5月正式出版的《中国特色医疗金鉴》登载的刘君主任及其机构事迹 |
| |
|
|
New vaccines may weaken the virus, HIV
At 1:39 on October 1, 2011 Source: Strait Metropolis Daily, according to Xinhua News Agency Xinhua
WASHINGTON some foreign researchers said a new AIDS vaccine has entered the human testing stage, is expected to weaken the virus, it can only lead to "mild chronic infection." The vaccine called MVA-B, the smallpox vaccine as the main development, adding no replication of HIV genes.
24 people have been using
Mice and monkeys to test the success of targeting the vaccine to enter human testing phase. British "Daily Mail" reported on 29 September and 30 healthy volunteers to join the test, 24 of whom use of vaccines and vaccine use another six similar-looking placebo, to rule out the placebo effect.
In fact, the placebo does not contain any pharmaceutical ingredients. However, some patients taking placebo, is expected to change due to mental illness appeared to ease. This phenomenon is called the placebo effect.
Test results showed that 90% of the volunteers show an immune response to HIV, 85% of the volunteers of the immune response can be maintained at least a year. "Daily Mail" reported that no mention of the vaccine and placebo groups, the specific test results.
Effect over other vaccines
AIDS vaccine research is the scientific community continue to work toward, but difficult. 2009, involving 16,000 volunteers in Thailand a study shows that a vaccine can prevent some of the people infected with AIDS, but only 30% efficient.
Senior professor of the Spanish Research Council Esteban said: "MVA-B vaccine and other existing certified (AIDS) vaccine as effective as, or even more effective."
Esteban statement in accordance with the mechanism of vaccine against AIDS, "is like show a picture of HIV", as the body's immune system recognizes the virus template.
The virus can weaken the impact of
In fact, MVA-B vaccine does not completely prevent the AIDS virus, but can weaken the virus affects the human body. Esteban that, according to this protective effect, MVA-B is fully qualified to be "promising vaccine."
"If (AIDS) virus into the body and try to replicate in cells, the immune system is ready to stop its activities and destroy the infected cells."
In other words, the MVA-B under the protection of the human body even if infected with HIV, it will not trigger serious complications, would lead to "mild chronic infection," Infectious significantly reduced. Some researchers say that if the vaccine successfully passed clinical testing phase, so the future impact of HIV on human herpes virus will be similar to the present.
|
